The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Spanish experience with the ipilimumab Expanded Access Program.
Alfonso Berrocal
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Jose A. Lopez-Martin
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Ana Maria Arance
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
V. Soriano
No relevant relationships to disclose
Enrique Espinosa
No relevant relationships to disclose
M Pilar Lopez Criado
No relevant relationships to disclose
Eva Muñoz
No relevant relationships to disclose
Jose Pablo Berros
No relevant relationships to disclose
A Soria
No relevant relationships to disclose
I Marquez
No relevant relationships to disclose
P Sancho
No relevant relationships to disclose
I Gil
No relevant relationships to disclose